| Title: |
METHODS OF INHIBITING SEIZURE IN A SUBJECT |
| Document Number: |
20090281522 |
| Publication Date: |
November 12, 2009 |
| Appl. No: |
12/179856 |
| Application Filed: |
July 25, 2008 |
| Abstract: |
The present invention relates to methods of inhibiting seizure in a subject. In particular, the invention provides methods of increasing brain leptin levels in a subject. |
| Inventors: |
Thio, Kwee Liu Lin (St. Louis, MO, US); Yamada, Kelvin A. (St. Louis, MO, US) |
| Assignees: |
Washington University in St. Louis (St. Louis, MO, US) |
| Claim: |
1. A method of inhibiting seizures in a subject, the method comprising intranasally administering a composition comprising leptin to the subject. |
| Claim: |
2. The method of claim 1, wherein the seizures are focal or general seizures. |
| Claim: |
3. The method of claim 1, wherein the subject is human. |
| Claim: |
4. The method of claim 1, wherein the composition comprises a leptin polypeptide having at least about 4 amino acids. |
| Claim: |
5. The method of claim 1, wherein the composition comprises a leptin polypeptide having at least any 4 contiguous amino acids from a primary amino acid sequence at least 75% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 2. |
| Claim: |
6. A method of inhibiting seizures in a subject, the method comprising administering a compound that activates the leptin receptor in the brain of the subject. |
| Claim: |
7. The method of claim 6, wherein the compound comprises a leptin receptor activator selected from the group consisting of a polypeptide, non-polypeptide, and combinations thereof. |
| Claim: |
8. The method of claim 7, wherein the polypeptide is a leptin polypeptide having at least about 4 amino acids. |
| Claim: |
9. The method of claim 7, wherein the polypeptide is a leptin polypeptide having at least any 4 contiguous amino acids from a primary amino acid sequence at least 75% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 2. |
| Claim: |
10. The method of claim 7, wherein the non-polypeptide is a small molecule agonist having the ability to bind to the leptin receptor and activate signaling pathways selected from the group consisting of JAK/STAT, P13, and combinations thereof. |
| Claim: |
11. The method of claim 6, wherein the compound activates the leptin receptor such that the brain leptin levels are increased to greater than about 15 pg/mg in the subject. |
| Claim: |
12. The method of claim 6, wherein the compound activates the leptin receptor such that the brain leptin levels are increased to greater than about 20 pg/mg in the subject. |
| Claim: |
13. The method of claim 6, wherein the compound is administered mucosally. |
| Claim: |
14. The method of claim 6, wherein the compound is administered intranasally. |
| Claim: |
15. A method of inhibiting seizures in a subject, the method comprising administering a composition comprising leptin to the subject, such that the brain leptin levels are increased to greater than about 15 pg/mg in the subject. |
| Claim: |
16. The method of claim 15, wherein the brain leptin levels are increased to greater than about 20 pg/mg in the subject. |
| Claim: |
17. The method of claim 15, wherein the composition comprises a leptin polypeptide having at least about 4 amino acids. |
| Claim: |
18. The method of claim 15, wherein the composition comprises a leptin polypeptide having at least any 4 contiguous amino acids from a primary amino acid sequence at least 75% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 2. |
| Claim: |
19. The method of claim 15, wherein the composition is administered mucosally. |
| Claim: |
20. The method of claim 15, wherein the composition is administered intranasally. |
| Current U.S. Class: |
604/522 |
| Current International Class: |
61 |
| Accession Number: |
edspap.20090281522 |
| Database: |
USPTO Patent Applications |
